2018: Strongest Start for Healthcare Dealmaking in Over a Decade


Healthcare companies have announced almost $30 billion of acquisitions since the beginning of the year. “As Big Pharma is confronted with drugs going off patent and weak research and development pipelines, they have no choice but to do significant acquisitions despite pushing valuation metrics,” said S&C partner Frank Aquila. "The new US tax law puts more cash in buyers’ hands and lower rates make more deals accretive. It’s a powerful combination."

Related Articles

U.S. Tax Bill to Stimulate M&A Activity

International Financial Law Review

Increased Corporate Cash to Bring More M&A Deals...

The American Lawyer

Has Deregulation Been Good for Business?